Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Theknocker91on Apr 29, 2020 2:43pm

105 Views

Post# 30967645

Possible that they're selling the gvhd program?

So there was an abrupt cancellation of LOI with stero, which is when their news releases stopped mentioned gvhd in the articles or in the 'about kalytera Therapeutics' section of the articles. On the main page for kaly on tmxmoney, under 'description', it no longer mentions gvhd. The release from april 13th mentions talks with companies to 'expand and diversify operations' which could mean they're selling the rights to their gvhd program and using those funds to pay debts and fund all of their other programs. This would be much better than acquiring stero and could give shareholders some returns quickly.

<< Previous

Bullboard Posts

Next >>

Silver Range Resources: A hidden gem in the mining industry